

JAN 27 1986

Nuclear Materials Safety Section B Division of Radiation Safety and Safeguards Nuclear Regulatory Commission Region 1 631 Park Avenue King of Prussia, Pennsylvania 19406 In Reply Refer To: 632/11E

SUBJ: Renewal of License # 31-13511-04 Control No. 13478

Dear Ms. Jenny M. Johansen:

In reference to your letter dated Nov 22, 1985 regarding our application of License renewal (License # 31-13511-04) the following information is hereby provided:

- 1. It was an oversight that the description of our constancy test excluded the statement attesting to the measurement of the Cs-137 source on the Cs-137 setting prior to measurement of the commonly used radionuclide settings. However, it is accomplished daily as part of our constancy check. Also, procedures described in C.1, C.7 and C.9 of Appendix D, Section 2 of Regulatory Guide 10.8 are presently followed.
- Item #14 is now changed to clarify and tighten up exceptions to safe opening procedures. (See copy of attached proposed amendment.)
- 3. Group VI sealed sources are still to be used. We would like to decrease our Maximum Possession Limit from 1 curie to 200 millicuries. The Physicians to be authorized are: Dr. Alice Lui, Dr. Sultan Ahmad, and Dr. Tae Lyong Park.
- 4. Total maximum possession limits desired for each radionuclide as listed in Item 6.b. of our application are listed on attachment #3.
- 5. We would like a total of 3 millicuries as a Maximum Possession Limit for in vitro kits as listed in 10 CFR 31.11 for clinical testing.
- 6. Sources acquired for Group VI uses as specified in 10 CFR 35.100 will not be used for instrument calibrations.

Sincerely,

8603270341 860315 REG1 LIC30 31-13511-04 PDR FEE EVEND

HILLIAM H. MANLEY Inley

Director

Enclosures: Attachments 1 thru 3.

113478

FEB 04 1996

"OFFICIAL RECORD COPY"

c. Measurement of exposure rate at the surface of the package will be made with the survey meter ON as the package is approached. If the surface exposure rate exceeds 10mR/hr., measurement at 1 meter distance will be made also. If the exposure rate exceeds 10mR/hr. at 1 meter or 200mR/hr. on contact, the RSO or Deputy RSO will be immediately notified.

d. Wipe tests will be made on the outer package surface and removed to a low background area for counting with a thin window GM counter. If any removable contamination is noted, the RSO or Deputy RSO will be immediately notified.

e. The package will be opened and the integrity of the final source container examined. In addition, the requisition (receiving report), packing slip and inner container labels will be compared to verify that the proper material has been delivered. If any damage or leakage is noted, or if any radioactive material was delivered in error, or if the material in the package together with other material at hand exceed the possession limits for the user, the RSO or Deputy RSO will be immediately notified.

f. Wipe tests as described in d above will be performed on all final source containers (1 wipe test per package suffices when the final source containers contain no more than ten times the quantity specified in Appendix C of 10 CFR Part 20). If any removable contamination is noted, the RSO or Deputy RSO will be immediately notified.

g. Survey will be made of all packages and packing material for contamination before discarding. If contaminated, these materials will be treated as radioactive waste. If not contaminated, radiation labels will be defaced before discarding in the regular trash.

h. Records of the results from the above testing will be recorded on a form similar to that on the following page.

Packages which are received directly from a commercial manufacturer of radionuclides or biochemicals, which are clearly unopened and undamaged (i.e. no crushed surfaces, damp spots, stained external surfaces, etc.), and which present no evidence of abnormality during the epening procedure, may be exempted from certain steps above as follows:

VA Medical Center, Northport, NY 11768
Rénewal of License No. 3213511-04

NRC Form 313M, Item 14, Page 2

- 1. Packages containing final source containers which do not exceed the unit amounts specified in 10 CFR 31.11, may be exempted from the requirements in C, D, F, G, & H above. Radioactive labels are defaced before discarding.
- 2. Packages which do not bear a DOT yellow Radioactive II or III label, may be exempted from the requirements in C or D above at the judgment of the RSO or Deputy RSO when they are opened by them personally.

NRC Form 313M, Item #4 (Amended 1/86)
INDIVIDUAL USERS

1. W.W. Shreeve, M.D., Ph.D.

Uses limited to in vitro studies, to Groups I thru V, to Xe-133 for blood flow and/or pulmonary function studies, and to investigational drugs.

2. J.L. Bateman, M.D.

Uses limited to in vitro studies, to Groups I thru V, and Xe-133 for blood flow and/or pulmonary function studies, and to investigational drugs.

3. Richard Singer, M.D.

Uses limited to in vitro studies.

4. W.R. Brugge, M.D.

Uses limited to 0.05mC1 of Co-58 in Schilling tests.

5. T.A. Johnson, CHP

Uses limited to calibrations and tests, shipping and receiving, and to storage.

6. Alice Lui, M.D.

Uses limited to 10 CFR 35.100, Schedule A, Group VI.

7. Sultan Ahmad, M.D.

Uses limited to 10 CFR 35.100, Schedule A, Group VI.

8. Tae Lyong Park, M.D.

Uses limited to 10 CFR 35.100, Schedule A, Group VI.

9. H.E. Carlson, M.D. *

10. J.F. DiStefano, M.D. *

11. M.L. Graber, M.D. *

12. R.J. Hitzeman, Ph.D. *

13. G.J. Kaloyanides, M.D. *

14. H. Kawanishi, M.D., Ph.D. *

15. B.W. Little, M.D. Ph.D. *

16. E. Pastoriza, M.D. *

17. S. Zucker, M.D. *

* Uses for the users limited to Research and Development

NRC Form 313M, Item 6.b. (Amended 11/84)
RADIOACTIVE MATERIAL FOR USES NOT LISTED IN ITEM 6.a. (Page 1 of 8)

USER: Total Maximum Possession Limit for Research & Development Personnel (Individual Possession Limits on subsequent pages)

PURPOSE OF USE:

Research and Development

Element and Mass Number	Chemical and/or Physical	Form			Possession Item, mCi
H-3	Any Form			200	mC1
C-14	any Form			100	mC1
P-32	Any Form			. 25	mC1
S-35 .	Any Form		-	2	mC1
Cr-51	Any Form			7	mC1
Fe-59	Any Form		1	3	mC1
I-125	Any Form			25	mC1
C1-36	Any Form			0.1	mCf
Ca-45	Any Form			1	mCf

NRC Form 313M, Item 6.b. (Amended 11/84)
RADIOACTIVE MATERIAL FOR USES NOT LISTED IN ITEM 6.a. (Page 2 of 8)

USER: J.F. DiStefano, M.D.; Research Service (Individual Possession Limit)

Element and Mass Number	Chemical and/or Physical Form	Maximum Possession Per Line Item, mCi
H-3	DFP, nucleic acid derivatives	1
H-3	borohydride salt and biochemicals labeled from borohydride	25
C-14	aldehydes & derivatives, amino acids, nucleic acid derivatives, ethanolamine phosphatidylcholine	1
P-32	ATP, DFP, Orthophosphate	10
S-35	amino acids and derivatives	1
Cr-51 ,	CrCl ₂ or other salt	0.5
Fe-59	FeCl ₃ or other salt	1
1-125	NaI or other salt :	5
1-125	nucleic acid derivatives	0.2

NRC Form 313M, Item 6.b. (Amended 11/84)
RADIOACTIVE MATERIAL FOR USES NOT LISTED IN ITEM 6.a. (Page 3 of 8)

USER: M.L. Graber, M.D.; Research Service (Individual Possession Limit)
PURPOSE OF USE: Research and Development

Element and Mass Number	Chemical and/or Physical Form	Maximum Possession Per Line Item, mCi
H-3 or C-14	DMO (dimethyloxazolidinedione)	1
H-3 or C-14	Inulin and other saccharides and- derivatives	1
H-3	H ₂ 0	10

NRC Form 313M, Item 6.b. (Amended 11/84)
RADIOACTIVE MATERIAL FOR USES NOT LISTED IN ITEM 6.a. (Page 4 of 8)

USER: G.J. Kaloyanides, M.D.; Research Service (Individual Possession Limit)

Element and Mass Number	Chemical and/or Physical Form	Maximum Possession Per Line Item, mCi
H-3 or C-14	amino acids and derivatives, amino- glycosides, and nucleic acid derivatives	. 60
P-32	orthosphosphate salt and biochemical derivatives	1
1-125	labeled biochemicals, liquid and solid	0.5

NRC Form 313M, Item 6.b. (Amended 11/84)
RADIOACTIVE MATERIAL FOR USES NOT LISTED IN ITEM 6.a. (Page 5 of 8)

USER: H. Kawanishi, M.D., Ph.D.; Research Service (Individual Possession Limit)
PURPOSE OF USE: Research and Development

Element and Mass Number	Chemical and/or Physical Form	Maximum Possession Per Line Item, mCi
H-3	Nucleic acid derivatives	10
Cr-51	Ma,CrO, or other salt and biochemical derivatives	. 5
1-125	NaI or other salt and biochemical derivatives	. 1

NRC Form 313M, Item 6.b. (Amended 11/84)
RADIOACTIVE MATERIAL FOR USES NOT LISTED IN ITEM 6.a. (Page 6 of8)

USER: E. Pastoriza, M.D.; Research Service (Individual Possession Limit)

Mass Number	Chemical and/or Physical Form			um Possession ine Item, mCi	
H-3	Inulin and other saccharides			10	
C-14	Inulin and other saccharides	-		2.5	
H-3 or C-14	Amino acids and saccharides			2	
P-32	Inorganic salt			10	
C1-36	Inorganic salt			0.1	
Ca-45	Inorganic salt		1	1	

NRC Form 313M, Item 6.b. (Amended 11/84)
RADIOACTIVE MATERIAL FOR USES NOT LISTED IN ITEM 6.a. (Page 7 of 8)

USER: S. Zucker, M.D.; Research Service (Individual Possession Limit)

Element and Mass Number	Chemical and/or Physical Form	Maximum Possession Per Line Item, mCi
H-3	labeled biochemicals, liquid and solid	20
H-3	borohydride salt and biochemicals labeled from borohydride	25
C-14 .	labeled biochemicals, liquid and solid	20
S-35	Methionine and other amino acids and derivatives	,
Cr-51	Na ₂ CrO ₄ or other salt	
Fe-59	FeC6H607 or other salt	2
I-125	labeled biochemicals, liquid and solid	5

NRC Form 313M, Item 6.b. (Amended 11/84)
RADIOACTIVE MATERIAL FOR USES NOT LISTED IN ITEM 6.a. (Page 8 of 8)

USER: T.A. Johnson, CHP, RSO (Individual Possession Limit)

PURPOSE OF USE: Radiation Safety; including Radioactive Waste Storage

Element and Mass Number	Chemical and/or Physical Form	Maximum Possession Per Line Item, mCi
H-3	Sealed sources, and other forms	
C-14	mentioned elsewhere on this	130
P-32	license application	20
S-35		. 100
C1-36		1
Ca-45		0.1
Cr-51*		1
Mn-54*		5
		0.01
Co-58	[[[경기] [] [[] [] [] [] [] [] [] [] [] [] []	0.1
Fe-55		25
Fe-59		3
20-60		0.01
Zn-65*		0.01
Se-75		0.5
Mo-99/Tc-99m		3 \$60
Cd-109		0.01
I-125		10
I-129		0.01
I-131		
Xe-133		400
Ba-133		20
Cs-137 •		0.5
Ce-144/Pr-144		170
Po-210		0.01
Am-241		0.01
		0.1